Curiva

Curiva

医疗设备

South Bend,Indiana 737 位关注者

关于我们

Curiva's mission is to provide customers with a non-invasive platform for diagnosing gynecologic malignancies such as cervical cancer. Our products allow doctors, healthcare professionals and patients to test in a sensitive way by delivering same-day analysis, and easier patient-centered results.

网站
https://curiva.co
所属行业
医疗设备
规模
2-10 人
总部
South Bend,Indiana
类型
私人持股
创立
2020

地点

Curiva员工

动态

  • Curiva转发了

    查看Peter Walker的档案,图片
    Peter Walker Peter Walker是领英影响力人物

    Head of Insights @ Carta | Data Storyteller

    Founders - use our current benchmark data to help raise your next VC round. Broken out into 25th, 50th, and 75th percentiles so you can place your fundraise within the broad current market. ???????????????????? ? All numbers in the chart below are post-money valuations for primary rounds in Q3 2024. ? Solid growth in Seed and Series A valuations from Q2. ???????? ???????????? ? All numbers reflect the total amount raised in a given round. ? Rounds have gotten larger at the 50th pct over the past year. ???????????????? ? Percentages in the chart reflect the total equity sold to investors in the round. For SAFE rounds, it reflects the expected ownership at conversion given the valuation cap. ? Dilution is calculated for each round independently - so you can't just read across the median valuation and round size to get the dilution figure! Other people will have different definitions of "pre-seed" - I get it! Amount raised in a SAFE round is the biggest determinant of the valuation cap. Also good to note that some of the pre-seed raises will probably end up raising more money on the same valuation cap. That part of the market is tricky. ?????? ???????????? ???? ???????? ?????????? ???? 1. Okay quarter. $20B invested into Carta startups, little less than Q2, little more than Q1. 2. Down rounds still hovering around 20% of all rounds. Still more kludge to work through from the boom times. 3. Dilution continues to center around 20% in Seed and Series A. 4. Time between rounds notched down for Seed to A, but up for A to B. Still good to plan for longer than you expect. 5. M&A bounceback? 170 companies acquired last quarter, the highest since 2022. Our full State of Private Markets report for Q3 is now live. Link in comments for the full report. If you want this graphic for your industry, give me shout that out in the comments below. Here's to a strong fundraising close & a better 2025! If you’d like more of our data in your inbox, subscribe today: https://lnkd.in/gNa_Dk-F

    • 该图片无替代文字
  • Curiva转发了

    查看Haya AlMana的档案,图片

    Day 2 #ZGI International #Accelorator in #SiliconValley #Networking Event We headed over to Nixon Peabody LLP as they hosted the live episode recording of Silicon Zombies Podcast by Nick Larson with Peter Walker, Keith Teare, and Alexander Johnson representing Carta, SignalRank and Velvet. The discussion was entreaging, focusing on the "The Future of Funding" . Sharing valuable findings and data on VC, IPO's and and how #AI is shifting data analysis, workflows and more ! Zain Kuwait Vibranium Venture Capitalp Zamir Shukho, MBA Saad Al Jassar #ZainGreatIdea

    • 该图片无替代文字
  • Curiva转发了

    查看Eydis L.的档案,图片

    Engineering Project Lead at C3 Medical | Founder at Curiva

    For all my fellow founders and CEOs out there. Check out this fantastic opportunity to apply and participate in the 2nd cohort of CancerX Moonshot! Apply!! Especially if your startup is in the pediatric oncology space. #cancermoonshots

    查看CancerX Moonshot的公司主页,图片

    5,432 位关注者

    ?? Announcing the 2025 CancerX Accelerator Program! ?? This year, we’re expanding with 300% more health system champions and a broader network of innovators dedicated to transforming cancer care. We're thrilled to welcome our champions Moffitt Cancer Center, KidsX, Advocate Health, Dana-Farber Cancer Institute, Flare Capital Partners, MassChallenge, Memorial Sloan Kettering Cancer Center, Mercury and Oncology Ventures. Our collaboration with KidsX also opens unique opportunities for startups in pediatric oncology. If you’re a startup focused on cancer care or pediatric health innovation, apply now to be part of our next cohort! More info: https://lnkd.in/gXd42i-8

    CancerX Startup Accelerator

    CancerX Startup Accelerator

    https://cancerx.health

  • Curiva转发了

    查看Eydis L.的档案,图片

    Engineering Project Lead at C3 Medical | Founder at Curiva

    This would be transformative!

    查看Bertalan Meskó, MD, PhD的档案,图片
    Bertalan Meskó, MD, PhD Bertalan Meskó, MD, PhD是领英影响力人物

    Director of The Medical Futurist Institute (Keynote Speaker, Researcher, Author & Futurist)

    Let's play with the what if question for a moment. Tomorrow, when you go to work, you will realize that you have to start working with and around a robot like this. Automation suddenly appears at the workplace in the form of an almost humanoid bot. How would that make you feel? Would you be excited to be around robots or would that make you angry? Would you fear your job due to the rise of automation?

  • Curiva转发了

    查看Eydis L.的档案,图片

    Engineering Project Lead at C3 Medical | Founder at Curiva

    Very critical for how healthcare will be delivered in the near future. #curiva #gynecologiccancers #breastcancerawarenessmonth #womenofscience

    查看Bertalan Meskó, MD, PhD的档案,图片
    Bertalan Meskó, MD, PhD Bertalan Meskó, MD, PhD是领英影响力人物

    Director of The Medical Futurist Institute (Keynote Speaker, Researcher, Author & Futurist)

    The spread of wearable digital technologies in healthcare generating big data entailed the appearance of a new type of medical information. They produce actionable insights into the biological state of individuals, just like “general” biomarkers, but are collected through digital tools. Here’s our summary of what digital biomarkers mean and how they will be used in the near future. You'll find the link to the article in the comments!

    • 该图片无替代文字
  • Curiva转发了

    查看Corinne Leach, PhD的档案,图片

    Digital Health Strategist, Digital Ventures Translator between Researchers and Startups, Behavioral Scientist, and Gerontologist

    A very exciting new partnership between Moffitt and AZ. Bringing patients new cell therapies faster. Together.

    查看Patrick Hwu的档案,图片

    President and CEO at Moffitt Cancer Center. To inspire and be inspired as a leader, focused on the future, relentlessly motivated in saving more lives.

    Moffitt Cancer Center is thrilled to collaborate with AstraZeneca. By combining our clinical expertise with AstraZeneca's innovative pipeline of investigational cell therapies, global footprint and leadership in oncology, we aim to bring potential new cell therapies to patients faster and more efficiently. ??: https://lnkd.in/emtWn4nj #CancerResearch #CellTherapy #Oncology #CancerCare

    • 该图片无替代文字
  • Curiva转发了

    查看Carolee Lee的档案,图片

    CEO & Founder of WHAM | TIME100 Health

    As we reflect on the first half of 2024, it's encouraging to see the strides we've made in the world of women’s health. This momentum?give us a renewed sense of purpose and energy as we move into the second half of the year. ? This year has already been uplifting, and I'm excited to share some key highlights from a recent Forbes article that underscore the progress and innovation happening in our field: ? ???$679.48M?raised by women’s health companies in H1 2024, setting a new midyear record. ???$12.58M: the highest average deal size seen in recent years. ?? A significant increase in?$50M+?fundraising rounds, reflecting growing confidence in this sector. ? These achievements are in alignment with the White House's Executive Order on Advancing Women's Health and the unwavering support of leaders across the ecosystem. ? However, according to the author of the article, Eva Epker, Director of Marketing at Avestria Ventures, “Since 2019, an average of 2.1% of the VC funding invested in healthcare companies has gone to women’s health companies by the half-year point and an average of 2.7% has gone to them by the year’s end. In 1H 2024, women’s health companies received about 2.5% of this funding".?Although this is moving in the right direction, it is still a very small percent of VC funding – which is why WHAM is focused on doubling that number through our 3Not30 goals and innovative partnerships. ? We all need to advocate for equitable funding and support for women’s health, recognizing the vast potential within this field. How else will we ensure that this upward trend not only continues, but flourishes? ? Image Credit: Getty https://lnkd.in/eseFi5AP ? #WomensHealth #HealthcareInnovation #WHAMNow #3Not30 #HealthEquity

    The State Of Investments In Women’s Health, Halfway Through 2024

    The State Of Investments In Women’s Health, Halfway Through 2024

    social-www.forbes.com

  • Curiva转发了

    查看Eydis L.的档案,图片

    Engineering Project Lead at C3 Medical | Founder at Curiva

    What a fantastic way to wrap up this chapter of graduating Curiva as a CancerX Moonshot inaugural startup last week in Boston!! Stay tuned for what lies ahead with our amazing champions Moffitt Oncology Network and Atrium Health! Thank you to the entire CancerX Moonshot team and the MassChallenge folks who made this accelerator an extraordinary experience for us and our team. Onwards and Upwards! "If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off... no matter what they say." ~Barbara McClintock - Nobel-Prize-winning geneticist, the first (and, so far, only) woman to win an unshared prize in Physiology or Medicine. ???? ?? ?

    查看CancerX Moonshot的公司主页,图片

    5,432 位关注者

    ?? CancerX is thrilled to announce the graduation of the 16 startup companies from the first cohort of our Accelerator program! Over four months, the Startups engaged in 16 curriculum sessions led by CancerX Accelerator Champions and Mentors. Topics included business scaling, government innovation, frontline healthcare, and industry partnerships, which assisted the startups in growing their businesses in various areas. By graduating from the Accelerator program, these startups now have a roadmap to successfully scale their company, an opportunity to move forward with their sponsor, and a strong community supporting their development. Because of the collaboration, support, and incredible contributions between Startups, Champions, and Mentors in the Accelerator program, the inaugural class is generating and scaling ideas that have the potential to save lives and improve the experience of cancer patients and their caregivers. The success of the CancerX Accelerator program is yet another milestone for CancerX in achieving our mission in support of Cancer Moonshot, and the potential to win the battle against cancer is within our grasp. ?? After the incredible success of the first Cohort, we’re thrilled to offer you the chance to be involved in our next cohort! Submissions for Cohort 2025 will open soon, and if you want to join the CancerX Accelerator as a startup, Champion, or mentor, be the first to hear about the details for Cohort 2025 by signing up here: https://lnkd.in/ebpXGwXa The Blue Box Biomedical Solutions, C the Signs, Cancer Insights, Curiva, EnteroTrack LLC., Gesund.ai, Gray Oncology Solutions, Lind, Mika, Navya Care, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, XanthosHealth

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • Curiva转发了

    查看Eydis L.的档案,图片

    Engineering Project Lead at C3 Medical | Founder at Curiva

    What a fantastic way to wrap up this chapter of graduating Curiva as a CancerX Moonshot inaugural startup last week in Boston!! Stay tuned for what lies ahead with our amazing champions Moffitt Oncology Network and Atrium Health! Thank you to the entire CancerX Moonshot team and the MassChallenge folks who made this accelerator an extraordinary experience for us and our team. Onwards and Upwards! "If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off... no matter what they say." ~Barbara McClintock - Nobel-Prize-winning geneticist, the first (and, so far, only) woman to win an unshared prize in Physiology or Medicine. ???? ?? ?

    查看CancerX Moonshot的公司主页,图片

    5,432 位关注者

    ?? CancerX is thrilled to announce the graduation of the 16 startup companies from the first cohort of our Accelerator program! Over four months, the Startups engaged in 16 curriculum sessions led by CancerX Accelerator Champions and Mentors. Topics included business scaling, government innovation, frontline healthcare, and industry partnerships, which assisted the startups in growing their businesses in various areas. By graduating from the Accelerator program, these startups now have a roadmap to successfully scale their company, an opportunity to move forward with their sponsor, and a strong community supporting their development. Because of the collaboration, support, and incredible contributions between Startups, Champions, and Mentors in the Accelerator program, the inaugural class is generating and scaling ideas that have the potential to save lives and improve the experience of cancer patients and their caregivers. The success of the CancerX Accelerator program is yet another milestone for CancerX in achieving our mission in support of Cancer Moonshot, and the potential to win the battle against cancer is within our grasp. ?? After the incredible success of the first Cohort, we’re thrilled to offer you the chance to be involved in our next cohort! Submissions for Cohort 2025 will open soon, and if you want to join the CancerX Accelerator as a startup, Champion, or mentor, be the first to hear about the details for Cohort 2025 by signing up here: https://lnkd.in/ebpXGwXa The Blue Box Biomedical Solutions, C the Signs, Cancer Insights, Curiva, EnteroTrack LLC., Gesund.ai, Gray Oncology Solutions, Lind, Mika, Navya Care, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, XanthosHealth

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字

相似主页

查看职位

融资